Get started
Author

Anna Turletti

Observed names: A Turletti, A. Turletti, Turletti, Anna
Institution: Ospedale Martini
Observed institutions: Università Cattolica del Sacro Cuore, University of Udine, University of Trieste, University of Chieti-Pescara, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Ospedale Sant'Anna, Azienda Ospedaliera San Gerardo, Federico II University Hospital, Azienda Socio Sanitaria Territoriale Lariana, Ospedale Martini, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Ospedale Policlinico San Martino, Candiolo Cancer Institute, Instituto Nazionale Tumori Regina Elena, Ospedale di Macerata, University of Florence, University of Turin, University of Naples Federico II, Sapienza University of Rome
ORCID: 0000-0003-1156-5077
Observed ORCID: 0000-0003-1156-5077
OpenAlex ID: A5070419785
Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients
1999 · Graziella Bellone, Anna Turletti, et al. · American Journal Of Pathology · 228
PDF
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
2015 · Lucia Del Mastro, Sabino De Placido, et al. · The Lancet · 213
Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1
1997 · Graziella Bellone, Stefania Silvestri, et al. · Journal of Cellular Physiology · 70
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
2022 · Lucia Del Mastro, Francesca Poggio, et al. · The Lancet Oncology · 59
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
2019 · M.E. Cazzaniga, G. Pinotti, et al. · The Breast · 56
Bone Marrow Stroma-Derived Prolactin Is Involved in Basal and Platelet-Activating Factor–Stimulated In Vitro Erythropoiesis
1997 · Graziella Bellone, Paola Astarita, et al. · Blood · 50
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
2016 · Matteo Lambertini, Marcello Ceppi, et al. · European Journal of Cancer · 43
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
2017 · Pier Franco Conte, Giancarlo Bisagni, et al. · Journal of Clinical Oncology · 36
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
2023 · Matteo Lambertini, Eva Blondeaux, et al. · EClinicalMedicine · 32
PDF
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
2023 · PierFranco Conte, Giancarlo Bisagni, et al. · Journal of Clinical Oncology · 26
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017 · M.E. Cazzaniga, M. Airoldi, et al. · The Breast · 22
Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
2019 · Matteo Lambertini, Francesca Poggio, et al. · International Journal of Cancer · 21
PDF
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
2021 · M. E. Cazzaniga, I. Vallini, et al. · Breast Cancer Research and Treatment · 18
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
2021 · Fabio Puglisi, Lorenzo Gerratana, et al. · npj Breast Cancer · 11
PDF
Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study
2013 · F Cognetti, P Bruzzi, et al. · Cancer Research · 11
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials
2024 · Eva Blondeaux, Wanling Xie, et al. · EClinicalMedicine · 9
PDF
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
2023 · Benedetta Conte, Luca Boni, et al. · Clinical Cancer Research · 9
PDF
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.
2023 · Pier Franco Conte, Giancarlo Bisagni, et al. · Journal of Clinical Oncology · 7
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024 · F. Poggio, E. Blondeaux, et al. · ESMO Open · 6
PDF
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
2023 · B. Trevisan, F. F. Pepe, et al. · Scientific Reports · 6
PDF
Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): Individual patient-level analysis from five mammella interGruppo (MIG) and gruppo italiano mammella (GIM) randomized clinical trials (RCTs).
2023 · Davide Soldato, Eva Blondeaux, et al. · Journal of Clinical Oncology · 4
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
2018 · Marina Cazzaniga, The EVA Study Group, et al. · Oncotarget · 4
PDF
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports
2018 · Guido Giordano, Antonio Febbraro, et al. · Oncology · 3
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
2023 · Marina Elena Cazzaniga, Paolo Pronzato, et al. · Cancers · 2
PDF
Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study
2017 · M. Cazzaniga, G. Mustacchi, et al. · Annals of Oncology · 2
PDF
Works count: 90
Citation count: 971
H-index: 14
I10-index: 16
Year
Topic
Type